排序方式: 共有41条查询结果,搜索用时 15 毫秒
1.
2.
Kurt Seetoo Maria Paz Carlos David Blythe Leena Trivedi Robert Myers Tracey England Criscelia Agee Bill Arnold Carolyn Dobbs Mary McIntyre Enrique Ramirez Julie Morita Saadeh Ewaidah Wilete Ishow Teresa Chou Kenneth Soyemi Albert E. Barskey Amy Parker Fiebelkorn Paul Lucas Emily S. Abernathy Joseph P. Icenogle Gregory S. Wallace Susan E. Reef Yoran Grant 《MMWR. Morbidity and mortality weekly report》2013,62(12):226-229
3.
4.
5.
Lelievre Benedicte Triau Stephane Codron Philippe Mariau Yoran Papin-Lefebvre Frederique Collin Alexandre Drevin Guillaume Le Roux Gael Briet Marie Boels David Letournel Franck 《Forensic Toxicology》2020,38(2):505-510
Forensic Toxicology - In developed countries, lead intoxication is decreasing in adults as sources of contamination were considerably reduced. Hence, cases of lead encephalopathy have become... 相似文献
6.
Effects of sildenafil on cardiac structure and function,cardiopulmonary exercise testing and health‐related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension
下载免费PDF全文
![点击此处可从《European journal of heart failure》网站下载免费的PDF全文](/ch/ext_images/free.gif)
7.
Chaim Yoran MD Edward L. Yellin PhD Masatsugu Hori MD PhD Katsuhiko Tsujioka MD Sholomo Laniado MD Edmund H. Sonnenblick MD Robert W.M. Frater MD 《The American journal of cardiology》1983,52(10):1345-1349
The effects of increasing heart rate (HR) on the hemodynamics of acute mitral regurgitation (MR) were studied in 8 open-chest dogs. Filling volume, regurgitant volume and stroke volume were calculated from electromagnetic probe measurements of mitral and aortic flows. The left atrial-left ventricular systolic pressure gradient was measured with micromanometers. The calculated effective mitral regurgitant orifice area varied from 10 to 128 mm2, with a consequent regurgitant fraction (regurgitant volume/filling volume) of 24 to 62%. After crushing the sinus node, HR was increased stepwise from 90 to 180 beats/min by atrial pacing while maintaining aortic pressure constant. With increasing HR, filling volume, stroke volume, regurgitant volume and regurgitant time decreased; total cardiac output, forward cardiac output, regurgitant output, systolic pressure gradient, regurgitant fraction and the regurgitant orifice did not change; left ventricular end-diastolic pressure decreased; and left atrial v-wave amplitude increased. These results indicate that in acute experimental MR with a wide spectrum of incompetence, the relative distribution of forward and regurgitant flows did not change with large increases in HR. At rates >150 beats/min the atrial contraction occurs early and increases the amplitude of the left atrial v wave. This may contribute to the severity of pulmonary congestion in patients with MR. 相似文献
8.
9.
10.
What have we learned about heart failure with mid‐range ejection fraction one year after its introduction?
下载免费PDF全文
![点击此处可从《European journal of heart failure》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jan F. Nauta Yoran M. Hummel Joost P. van Melle Peter van der Meer Carolyn S.P. Lam Piotr Ponikowski Adriaan A. Voors 《European journal of heart failure》2017,19(12):1569-1573
The 2016 European Society of Cardiology heart failure guidelines introduced the term ‘heart failure with mid‐range ejection fraction’ (HFmrEF) to refer to patients with heart failure and a mildly reduced ejection fraction of 40–49%. About 20% of heart failure patients fall in this category. One of the main reasons for the introduction of this category was to stimulate research into this grey area. This review aims to highlight the key findings that have been published so far. Firstly, HFmrEF more closely resembles heart failure with reduced (HFrEF) than preserved ejection fraction (HFpEF) with regard to ischaemic aetiology, which is more frequent in both HFmrEF and HFrEF compared to HFpEF. Secondly, changes in ejection fraction over time are common, and seem to be more important than baseline ejection fraction alone. Patients who progress from HFmrEF to HFrEF have a worse prognosis than those who remain stable or transition to HFpEF. Lastly, and perhaps most importantly, retrospective analyses from a randomized trial suggest that patients with HFmrEF seem to benefit from therapies that have shown to improve outcome in HFrEF, whereas no such benefit was seen in patients with HFpEF. 相似文献